IPCA Laboratories Ltd
NSE:IPCALAB

Watchlist Manager
IPCA Laboratories Ltd Logo
IPCA Laboratories Ltd
NSE:IPCALAB
Watchlist
Price: 1 581.7 INR -0.26% Market Closed
Market Cap: 401.3B INR
Have any thoughts about
IPCA Laboratories Ltd?
Write Note

IPCA Laboratories Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

IPCA Laboratories Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
IPCA Laboratories Ltd
NSE:IPCALAB
Free Cash Flow
â‚ą9B
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Free Cash Flow
â‚ą8.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Free Cash Flow
â‚ą29.5B
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Free Cash Flow
â‚ą107.7B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Free Cash Flow
â‚ą29.3B
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Free Cash Flow
â‚ą17.6B
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

IPCA Laboratories Ltd
Glance View

Market Cap
401.3B INR
Industry
Pharmaceuticals

In the bustling corridors of the global pharmaceutical industry, IPCA Laboratories Ltd. stands as a formidable presence, deeply rooted in its commitment to innovative healthcare solutions. Established with a mission to enhance patient well-being, IPCA has grown from a modest formulation company in India into a multinational endeavor, celebrated for its prowess in the realms of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. This vertically integrated company meticulously controls every element of its production chain, securing its position as a trusted supplier to some of the world's leading pharmaceutical giants. IPCA's robust portfolio includes a wide array of therapeutic segments, from antimalarials and analgesics to antihypertensives and nutraceuticals, showcasing its versatility and comprehensive grasp over diverse medical needs. What sets IPCA apart in the crowded pharmaceutical landscape is its strategic blend of cutting-edge research, efficient manufacturing practices, and a global distribution network. The company invests significantly in research and development, channeling innovation into its drug development processes to sustain its competitive edge. Enhanced production capabilities at its state-of-the-art facilities ensure that IPCA not only meets stringent international standards but also operates at optimal cost efficiency. This enables the company to leverage economies of scale, thereby maximizing profitability. By exporting to over 100 countries and employing a robust marketing strategy, IPCA ensures its products have a wide reach across developed and emerging markets. Thus, through its integrated approach to drug development and distribution, IPCA Laboratories continues to cultivate a steady stream of revenue while contributing substantially to global healthcare.

IPCALAB Intrinsic Value
1 236.48 INR
Overvaluation 22%
Intrinsic Value
Price

See Also

What is IPCA Laboratories Ltd's Free Cash Flow?
Free Cash Flow
9B INR

Based on the financial report for Sep 30, 2024, IPCA Laboratories Ltd's Free Cash Flow amounts to 9B INR.

What is IPCA Laboratories Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
34%

Over the last year, the Free Cash Flow growth was 166%. The average annual Free Cash Flow growth rates for IPCA Laboratories Ltd have been 34% over the past three years .

Back to Top